Hutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor Study

Hutchison China MediTech HCM has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's BGNE tislelizumab in patients with advanced solid tumors in the U.S. and Europe.

• The open-label study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of the surufatinib and tislelizumab combination.
• The study consists of two parts:
• Dose-finding Part 1 will be conducted to determine the recommended Phase II dose ("RP2D") and the maximum tolerated dose of surufatinib/ tislelizumab combo in patients with advanced or metastatic solid tumors who have progressed on, or are intolerant to, standard therapies.
• Part 2 dose expansion will be an open-label, multi-cohort design to evaluate the anti-tumor activity of surufatinib/tislelizumab combo in patients with specific types of advanced or metastatic solid tumors.
• Surufatinib is an oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor and fibroblast growth factor receptor. It inhibits both angiogenesis and colony-stimulating factor-1 receptor, regulating tumor-associated macrophages, promoting the body's immune response against tumor cells.
• Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.
• Price Action: HCM shares closed 0.1% higher at $28.04, and BGNE shares closed 5.8% lower at $335.39 on Tuesday.